KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis (NCT06400303)

🧪 Interventions in This Study

• KYV-101 (BIOLOGICAL)
• Standard lymphodepletion regimen (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

• Stanford University Medical Center — Palo Alto, California
• Northwell Health — Great Neck, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Systemic Sclerosis

• Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) — Scottsdale, Arizona
• Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial — Charleston, South Carolina
• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis — Scottsdale, Arizona
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis — New York, New York
• Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis — Houston, Texas

Explore by condition: All Systemic Sclerosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.